Robert R. Redfield American medical researcher
Redfield, Robert R.
VIAF ID: 8153470923045082607 (Personal)
Permalink: http://viaf.org/viaf/8153470923045082607
Preferred Forms
-
100 1 _ ‡a Redfield, Robert R.
-
100 1 _
‡a
Redfield, Robert R.
-
100 1 _ ‡a Redfield, Robert R.
-
100 0 _
‡a
Robert R. Redfield
‡c
American medical researcher
4xx's: Alternate Name Forms (10)
Works
| Title | Sources |
|---|---|
| Active Tuberculosis Case Finding in Port-au-Prince, Haiti: Experiences, Results, and Implications for Tuberculosis Control Programs |
|
| Antibody-dependent cellular cytotoxicity in HIV type 1-infected patients receiving VaxSyn, a recombinant gp160 envelope vaccine |
|
| Assessment of gag DNA and genomic RNA in peripheral blood mononuclear cells in HIV-infected patients receiving intervention with a recombinant gp 160 subunit vaccine in a phase I study |
|
| Association of interleukin-6 in the pathogenesis of acutely fatal SIVsmm/PBj-14 in pigtailed macaques |
|
| Bartlett's medical management of HIV infection |
|
| Clinical performance of a polymerase chain reaction testing algorithm for diagnosis of HIV-1 infection in peripheral blood mononuclear cells. |
|
| Consequences of stable transduction and antigen-inducible expression of the human interleukin-7 gene on tetanus-toxoid-specific T cells |
|
| The current distribution of CD4+ T-lymphocyte counts among adults in the United States with human immunodeficiency virus infections: estimates based on the experience of the U.S. Army. U.S. Army Retrovirus Research Group. |
|
| Defective regulation of Epstein-Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related disorders |
|
| Delayed-type hypersensitivity skin testing using third variable loop peptides identifies T lymphocyte epitopes in human immunodeficiency virus-infected persons. |
|
| Diagnosis of human immunodeficiency virus infection by immunoassay using a molecularly cloned and expressed virus envelope polypeptide. Comparison to Western blot on 2707 consecutive serum samples |
|
| Differential human immunodeficiency virus-suppressive activity of reverse transcription inhibitors in resting and activated peripheral blood lymphocytes: implications for therapy |
|
| Disseminated vaccinia in a military recruit with human immunodeficiency virus |
|
| Effects of adjuvants and multiple antigen peptides on humoral and cellular immune responses to gp160 of HIV-1. |
|
| Establishment and characterization of human immunodeficiency virus type 1 (HIV-1) envelope-specific CD4+ T lymphocyte lines from HIV-1-seropositive patients |
|
| Expansion of restricted cellular immune responses to HIV-1 envelope by vaccination: IL-7 and IL-12 differentially augment cellular proliferative responses to HIV-1 |
|
| False-positive Western blot tests for antibodies to HTLV-III. |
|
| Fine specificity of the humoral immune response to HIV-1 GP160 in HIV-1 infected individuals from Tanzania |
|
| Frequent isolation of HIV-1 from the blood of patients receiving zidovudine (AZT) therapy |
|
| Genetic comparison of human immunodeficiency virus (HIV-1) isolates by polymerase chain reaction |
|
| HIV infection: the clinical picture |
|
| HIV neutralization assay using polymerase chain reaction-derived molecular signals |
|
| HIV-specific vaccine therapy: concepts, status, and future directions |
|
| Human immunodeficiency virus infections among civilian applicants for United States military service, October 1985 to March 1986. Demographic factors associated with seropositivity |
|
| Humoral responses to linear epitopes on the HIV-1 envelope in seropositive volunteers after vaccine therapy with rgp160 |
|
| Immunization of HIV-infected patients with rgp160: modulation of anti-rgp120 antibody spectrotype |
|
| Immunologic parameters in early-stage HIV-seropositive subjects associated with vaccine responsiveness |
|
| Immunotherapeutic strategies in the treatment of HIV infection and AIDS. |
|
| Induction of human immunodeficiency virus type 1 expression in chronically infected cells is associated primarily with a shift in RNA splicing patterns. |
|
| Inhibition of HIV replication by sense and antisense rev response elements in HIV-based retroviral vectors |
|
| Isolation of HIV-1 from the blood of seropositive adults: patient stage of illness and sample inoculum size are major determinants of a positive culture. The Walter Reed Retroviral Research Group |
|
| Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines |
|
| Long-term immunotherapy in HIV infection, combined with short-term antiretroviral treatment |
|
| Measurement of cerebrospinal fluid antibody to the HIV-1 principal neutralizing determinant (V3 loop) |
|
| Measurement of the False Positive Rate in a Screening Program for Human Immunodeficiency Virus Infections |
|
| Negative-strand RNA transcripts are produced in human immunodeficiency virus type 1-infected cells and patients by a novel promoter downregulated by Tat. |
|
| Oral hairy leukoplakia. A distinctive marker of human T-cell lymphotropic virus type III (HTLV-III) infection |
|
| Patterns of antibody recognition of selected conserved amino acid sequences from the HIV envelope in sera from different stages of HIV infection |
|
| Predictors of HIV-1 disease progression in early- and late-stage patients: the U.S. Army Natural History Cohort. Military Medical Consortium for Applied Retrovirology |
|
| Preferential antibody recognition of structurally distinct HIV-1 gp120 molecules |
|
| Prospective analyses of HIV-1-specific proliferative responses, recall antigen proliferative responses, and clinical outcomes in an HIV-1-seropositive cohort. |
|
| Proteosomes, emulsomes, and cholera toxin B improve nasal immunogenicity of human immunodeficiency virus gp160 in mice: induction of serum, intestinal, vaginal, and lung IgA and IgG. |
|
| Real-time biospecific interaction analysis of antibody reactivity to peptides from the envelope glycoprotein, gp160, of HIV-1 |
|
| Repeated immunization with recombinant gp160 human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: evaluation of the T cell proliferative response |
|
| Safety and immunogenicity of multiple conventional immunizations administered during early HIV infection |
|
| Sequential Dysfunction and Progressive Depletion of Candida albicans-Specific CD4 T Cell Response in HIV-1 Infection. |
|
| Serum IgA-mediated neutralization of HIV type 1 |
|
| Shadow on the Land: the epidemiology of HIV infection |
|
| Tracking the spread of the HIV infection epidemic among young adults in the United States: results of the first four years of screening among civilian applicants for U.S. military service |
|
| Transcriptional effects of superinfection in HIV chronically infected T cells: studies in dually infected clones |
|
| V3 seroreactivity and sequence variation: tracking the emergence of V3 genotypic variation in HIV-1-infected patients. |
|
| Vaccine therapy using rgp 160 in early HIV infection |
|
| Variations in Western blot banding patterns of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus |
|
| Viral DNA and mRNA expression correlate with the stage of human immunodeficiency virus (HIV) type 1 infection in humans: evidence for viral replication in all stages of HIV disease |
|
| The Walter Reed staging classification for HTLV-III/LAV infection. |
|
